Objective: Evaluate efficacy and safety of a 2-month formulation of aripiprazole lauroxil (AL) with 1-day initiation during hospitalization for acute exacerbation of schizophrenia followed by transition to outpatient care.
Methods: The phase 3b double-blind Aripiprazole Lauroxil and Paliperidone palmitate: INitiation Effectiveness (ALPINE) study was conducted from November 2017 to March 2019. Adults with acute schizophrenia according to DSM-5 criteria were randomized (1:1) to AL (AL NanoCrystal Dispersion + oral aripiprazole 30 mg, day 1; AL 1,064 mg, day 8 and every 8 weeks [q8wk]) or paliperidone palmitate (PP 234 mg, day 1; PP 156 mg, day 8 and then q4wk) for 25 weeks. Patients remained hospitalized ≥ 2 weeks after randomization per protocol. Primary endpoint was within-group change in Positive and Negative Syndrome Scale total score (PANSST) from baseline to week 4. Secondary analyses included within- and between-group changes from baseline at various time points. Adverse events (AEs) and laboratory data were monitored.
Results: A total of 200 patients were randomized (AL, n = 99; PP, n = 101); 56.6% and 42.6%, respectively, completed the study. For AL, the mean baseline PANSST was 94.1; scores were significantly reduced from baseline at week 4 (-17.4; P < .001) and were also reduced at weeks 9 (-19.8) and 25 (-23.3). With PP, PANSST also improved significantly from baseline (94.6) at week 4 (-20.1; P < .001) and also improved at weeks 9 (-22.5) and 25 (-21.7). The 3 most common AEs over 25 weeks in the AL group were injection site pain (17.2%), increased weight (9.1%), and akathisia (9.1%). The same AEs were the most common in the PP group (injection site pain [24.8%], increased weight [16.8%], and akathisia [10.9%]).
Conclusions: AL and PP were efficacious and well-tolerated for initiating treatment of schizophrenia in the hospital and continuing outpatient treatment.
Trial Registration: ClinicalTrials.gov identifier: NCT03345979.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.4088/JCP.19m13207 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Appropriate use of single-dose injectable aripiprazole lauroxil in the treatment of schizophrenia.
Ment Health Clin
December 2024
(Corresponding author) Associate Professor, Department of Clinical and Administrative Pharmacy, College of Pharmacy, University of Georgia, Athens, GA,
Introduction: Single-dose injectable aripiprazole lauroxil (SDIAL) is used with long-acting injectable (LAI) aripiprazole lauroxil in the treatment of schizophrenia. SDIAL can be used to either initiate treatment or supplement during maintenance when follow-up doses are not given within labeling recommendations. The primary objective was to determine the usage and appropriateness of SDIAL between the initiation and the maintenance supplementation use in a Medicaid database.
View Article and Find Full Text PDFLong-Acting Injectable Antipsychotic Initiation in Child and Adolescent Patients with Psychiatric Disorders.
J Child Adolesc Psychopharmacol
August 2024
UPMC Western Psychiatric Hospital, Pittsburgh, Pennsylvania, USA.
There are currently no long-acting injectable antipsychotics (LAIAs) that are approved by the Food and Drug Administration for use in child and adolescent patients, however these agents are used off-label for the treatment of various psychiatric disorders. This study aims to describe the initiation and maintenance dosing strategies of LAIAs in child and adolescent psychiatry inpatients. This was a single-site retrospective chart review of patients less than 18 years of age initiated on an LAIA during an acute psychiatric hospitalization between October 1, 2015, and October 31, 2022.
View Article and Find Full Text PDFInitiating Aripiprazole Lauroxil: Post Hoc Analysis of Safety and Tolerability of 1-Day and 21-Day Regimens.
J Clin Psychiatry
August 2024
Alkermes, Inc, Waltham, Massachusetts.
Article Synopsis
- Aripiprazole lauroxil (AL) is a long-acting injectable antipsychotic that can be initiated using either a 1-day or 21-day regimen, and this study analyzed their safety and tolerability.
- The post hoc analysis showed comparable adverse event rates between both regimens, with most events being mild, although some specific side effects (like injection site reactions and akathisia) were noted.
- The findings indicate that both initiation approaches are similarly safe, suggesting the importance of involving patients in selecting their treatment plan for schizophrenia.
A 16-Year-Old Male with Autism Spectrum Disorder, Psychosis, and Refusal to Accept Any Oral Medication: A Case Report and Use of Long-Acting Injectable Aripiprazole Lauroxil.
J Child Adolesc Psychopharmacol
July 2024
Winnebago Mental Health Institute, Winnebago, Wisconsin, USA.
Functioning and Cognition in Patients with Schizophrenia After Initiating Treatment with Aripiprazole Lauroxil: Secondary Outcomes and Post Hoc Analysis.
Innov Clin Neurosci
March 2024
Drs. Claxton, McGrory, Wang, and Yagoda and Ms. Gasper are with Alkermes, Inc. in Waltham, Massachusetts.
Background: Clinical practice guidelines support efforts to improve functioning in patients with schizophrenia. Discrepancies in the perception of cognitive status between clinicians, patients with schizophrenia, and their caregivers have been associated with impaired functional abilities in patients; medication side effects might worsen both cognition and daily functioning. We assessed daily/social functioning and cognition in stable patients with schizophrenia who switched to the long-acting injectable (LAI) antipsychotic aripiprazole lauroxil (AL).
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!